08/01/2014 - 20:20
Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been approved for the treatment of type 2 diabetes with a requirement that the manufacturer conduct postmarketing studies that address...
Field of Interest: Endocrinology
Categories:
News Feed: Internal Medicine News - Endocrinology